Hematology
Volume 23, 2018 - Issue 4
Open access
1,768
Views
3
CrossRef citations to date
0
Altmetric
Immune Thrombocytopenia
Tolerability and safety of the intravenous immunoglobulin octagam® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials
Stefan WietekOctapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
http://orcid.org/0000-0002-8838-6707View further author information
Daniel SvorcOctapharma Pharmazeutika Produktionsges.m.b.H., Vienna, AustriaCorrespondence[email protected]
View further author information
, View further author information
Anette DebesOctapharma GmbH, Langenfeld, GermanyView further author information
& Tor-Einar SvaeOctapharma Inc., Hoboken, NJ, USAView further author information
Pages 242-247
|
Published online: 11 Oct 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.